Sandoz Reveals Aflibercept Program
Kicks Off Phase III Trials For Biosimilar Version Of Eylea
Sandoz has revealed late-stage clinical development plans for an aflibercept biosimilar, setting out details of a Phase III trial for the proposed Eylea rival.
You may also be interested in...
Korea’s Alteogen believes that formulation patents granted in the EU, US and Japan as well as a pending process patent may offer it a first-mover advantage on biosimilar aflibercept. The firm has just completed a Phase I trial for its proposed rival to Eylea.
Celltrion has announced that its latest biosimilar development project is progressing to Phase III trials, with its aflibercept rival to Eylea following recent advances for the Korean firm’s denosumab, omalizumab and ustekinumab candidates.
Coherus BioSciences, a leader and innovator in the nascent US biosimilars space, has announced plans to ditch a key biosimilar opportunity and limit overall investment, in order to direct resources to immuno-oncology.